MS Trial Alerts for California

MS Trial Alert: Investigators in California, Recruiting for Study of Online Program to Treat Depression in All Forms of MS

SUMMARY: Investigators at three sites in the United States and two sites in Germany are recruiting 400 people with all forms of MS for a study testing the effectiveness of a computer training program for overcoming MS-related depression. The lead investigator is Stefan Gold, PhD, at Charité University in Berlin, Germany. The study is funded by the National MS Society. Please note: Two visits to a study site are required.

DETAILS
Rationale: Depression is a common symptom experienced by people living with multiple sclerosis. At the same time, MS symptoms such as walking difficulties, cognitive problems, and fatigue can make it difficult to attend sessions with a psychotherapist. Dr. Gold’s team recently conducted a small trial using a fully-automated, computer-based program to reduce depression in people with MS. The program can be accessed over the internet and completed from an individual’s home, eliminating the need to travel. The team’s preliminary results suggested that this program, called “Deprexis,” may reduce MS depression.

Dr. Gold and colleagues are now conducting a large-scale, phase III trial at five MS centers in Germany and the U.S. to test the effectiveness of the Deprexis computer training program in 400 people with MS.

Eligibility and Details: Participants should be over the age of 18, with a diagnosis of MS and symptoms of depression. They should be able to travel to a study site for two clinical assessments, and must have internet access at home. Further details are available by contacting the site nearest you.

Participants are being randomly assigned to one of three groups: One group will receive access to the web-based Deprexis program for three months; another group will receive the web-based Deprexis program plus scheduled e-mail contacts once each week for three months; and a third control group will be on a waiting list, and will receive Deprexis only after waiting six months.

The primary outcome being assessed is a clinical scale that measures depression. Other outcomes include measures of quality of life, cognitive function, and fatigue. Participants are being evaluated at the beginning of the study, and after three months, six months and 12 months. The first two evaluations require a visit to the study site at which they are enrolled, whereas the last two are completed online.

Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please contact the U.S. site nearest you:

Cedars-Sinai Medical Center
Los Angeles, California
Phone: (310) 423-4008
Email: Daniel.Perez2@cshs.org

The NeuroCommunity Foundation is here for you:

For information about Parkinson’s disease and other movement disorders, support groups, wellness programs, education events, and local resources in northern Los Angeles County, Ventura County, Central Coast & Central Valley, contact us here or call 818-745-5051 to speak with Jan D. Somers, MSW, LCSW, BCD, Education Director, Parkinson & Movement Disorder Information Center, The NeuroCommunity Foundation.

The NeuroCommunity Foundation is a non-profit foundation. We provide support groups, educational conferences, resources, research updates/ clinical trials information and PD events in the SFV/Ventura/Central Coast/ Inland Empire.

As we rely on donations to continue providing these services at no charge, if you would like to support our efforts, you can donate with ease and security at our website or mail us your gift. Please make sure and note our website as a bookmark in your computer. It is:  www.neurocommunity.org 

The NeuroCommunity Foundation is exempt from Federal income tax under section 501(c)(3) of the Internal Revenue Code. Donors may deduct contributions to the foundation as provided in section 170 of the Internal Revenue Code

Mailing Address: 

The NeuroCommunity Foundation                              

23705 Vanowen St. # 216                               

West Hills, CA 91307

NEW MS drug treatment Ocrevus approved from FDA

This information is from: NBC NEWS http://www.nbcnews.com

The Food and Drug Administration approved a new drug to treat multiple sclerosis Tuesday, March 28,2017

The drug, called Ocrevus, is approved for use against the most common form of MS – the relapsing-remitting type. It’s also the first drug specifically approved for primary progressive MS, a very aggressive form of the disease that affects 10 to 15 percent of MS patients.

There are no approved treatments now for primary progressive MS, which causes steadily worsening symptoms.

YOU CAN ALSO GO TO: MS News Update: FDA Approves First Drug to Treat Two Forms of MS – Please see MSAA’s online news article for more information. CLICK: mymsaa.org/news/fda-approves-ocrevus

While it’s not a cure, it’s one more weapon to use to help some of the 400,000 people with MS. In trials of 1,600 volunteers, it cut relapses in patients with the most common form of MS by nearly half compared with an older drug called Rebif.

Ocrevus, known generically as ocrelizumab, is a monoclonal antibody – an engineered immune system molecule. It won breakthrough designation from the FDA, which helped speed it through the approval process. Roche, which makes the drug, expects sales to top $4 billion a year.

It will be on the market within two weeks, and will cost $65,000 a year, the company said. That’s similar to the cost of Rebif, a 14-year-old drug now widely used to treat MS, although costs vary widely on all MS drugs.

Genentech says it deliberately set the price 20 percent below the current market average for an MS treatment. “The continually escalating prices of MS disease-modifying therapies are creating barriers to people with MS getting these life-changing medications,” the National MS Society said in a statement.

“Given every six months by IV infusion, Ocrevus represents a scientific advancement as a first-in-class therapy targeting B cells, a type of immune cell that plays a central role in the disease,” Genentech, a subsidiary of drug giant Roche, said in a statement.

[Read more…]

MS Clinical Trial Information

Clinical Trials Word Cloud

CURRENT MS CLINIAL TRIALS IN THE LOS ANGELES AREA

CLICK ON THE GREEN LINK TO TAKE YOU DIRECTLY TO THE CLINICAL TRIAL INFORMATION!

Closest site: Less than 5 miles away

Status: Enrolling participants

Trial type: Interventional (Drug)The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive… Read more

Closest site: USC Norris Comprehensive Cancer Center

Status: Enrolling participants

Trial type: Interventional (Drug)The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units… Read more

Closest site: CEDAR SINAI

Status: Not yet enrolling participants

Trial type: Interventional (Behavioral)This is an international, multicenter, randomized controlled trial of an internet-based CBT intervention for depression (Deprexis) conducted in… Read more

Closest site:  BURBANK

Status: Enrolling participants

Trial type: Observational (Drug)The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or… Read more

Looking for more options

New trials are being added all the time. Leave your email address and we will keep you updated as more options become available.   GO TO: https://antidote.me/match/study-page . If you click the colored word  STUDY – it will take you directly to the Antidote website where you can sign up for emails.

 

New hope for treament of MS

New hope for treatments of MS

 The passage of the 21st Century Cures Act will accelerate the discovery, development and delivery of life-changing treatments and improve the day-to-day lives of people with multiple sclerosis,” said Cyndi Zagieboylo, President and CEO of the National MS Society.

The bill includes a number of the MS movement’s top priorities:

  • Establishment of a data collection system to track the incidence and prevalence of neurological conditions, otherwise known as the Neuro Data bill;
  • $4.8 billion in new funding for the National Institutes of Health and $500 million for the Food and Drug Administration to bring new treatments to patients;
  • A six-month extension protecting access to power complex rehabilitation technology (CRT) wheelchair accessories, which are fundamental components of the chair such as tilt-and-recline systems and specialized seat cushions.

“I applaud Congress for creating a pathway for promising innovation through the establishment of a data collection system for neurological diseases; providing new funding for the NIH and the FDA; protecting access to CRT wheelchair accessories and more. This groundbreaking legislation truly brings us one step closer to ending MS,” said Zagieboylo.
“This will be a game-changer,” said MS District Activist Leader Frank Austin of Pennsylvania. Austin was diagnosed with MS in 1999 and was deeply involved in the passage of the bill. “I’ll continue to advocate over the next few years so the funding is appropriated and the bill is effectively implemented.”

Learn more:

The NeuroCommunity Foundation is here for you:

For information about Parkinson’s disease and other movement disorders, support groups, wellness programs, education events, and local resources in northern Los Angeles county, Ventura county, Central Coast & Central Valley, contact us here or call 818-745-5051 to speak with Jan D. Somers, Education Director, Parkinson & Movement Disorder Information Center, The NeuroCommunity Foundation.

The NeuroCommunity Foundation is a non-profit foundation. We provide support groups, educational conferences, resources, research updates/ clinical trials information and PD events in the SFV/Ventura/Central Coast/ Inland Empire.

As we rely on donations to continue providing these services at no charge, if you would like to support our efforts, you can donate with ease and security at our website or mail us your gift. Please make sure and note our website as a bookmark in your computer. It is:  www.neurocommunity.org

The NeuroCommunity Foundation is exempt from Federal income tax under section 501(c)(3) of the Internal Revenue Code. Donors may deduct contributions to the foundation as provided in section 170 of the Internal Revenue Code.

 

 

 

 

 

 

MS Clinical trials recruiting now

inspriation august

Multiple Sclerosis

HERE IS A LIST OF THE CURRENT CLINICAL TRIALS RECRUITING FOR MS PATIENTS 

1) Cedars-Sinai Medical Center – A Phase 2 Pharmacodynamics Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis. Contacts: Vy Nguyen & Ashley Fetterman. Emails: Vy.NguyenX@cshs.org & katherine.fetterman@cshs.org.   Phones: 424-315-2361 & 310-423-8497. Recruiting until 5/1/2017

2) Online – Cedars-Sinai Medical Center – Online Program to Reduce Depression in MS – a Multicenter Randomized Controlled Trial. Contact: Stefan M. Gold. Email: stefan.gold@charite.de. Recruiting until 4/1/2019

3) UCLA Department of Neurology – A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition. Contact: Jenny Bardens. Email: JBardens@mednet.ucla.edu. Phone: 310-206-2176. Recruiting until 7/1/2018

4) UCLA – Clinical Trial – Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and activity of Ibudilast (MN-166) in people with Progressive Multiple Sclerosis. Contact: Jenny Bardens. Email: JBardens@mednet.ucla.edu. Phone: 310-206-2176. Currently Recruiting

The NeuroCommunity Foundation is here for you!

As a non-profit foundation, we provide support groups, educational conferences, resources, research updates/ clinical trials information and PD events in the SFV/Ventura/Central Coast/ Inland Empire.

As we rely on donations to continue providing these services at no charge, if you would like to support our efforts, you can donate with ease and security at our website or mail us your gift. Our website is:  www.neurocommunity.org 

The NeuroCommunity Foundation is exempt from Federal income tax under section 501(c)(3) of the Internal Revenue Code. Donors may deduct contributions to the foundation as provided in section 170 of the Internal Revenue Code.

For information about Parkinson’s disease and other movement disorders, support groups, wellness programs, education events, and local resources in northern Los Angeles county, Ventura county, Central Coast & Central Valley, contact us here or call 818-885-8623 to speak with Jan D. Somers, Education Director, Parkinson & Movement Disorder Information Center, The NeuroCommunity Foundation.

 

 

Learn about the latest MS research

Image result for photo of research

Learn about the Latest MS Research

Each spring, the American Academy of Neurology (AAN) and the Consortium of Multiple Sclerosis Centers (CMSC) host their respective international conferences where thousands of multiple sclerosis healthcare professionals including neurologists, nurses, physical and occupational therapists and many other practitioners attend and present the latest MS research findings. In addition to attending these conferences, MSAA researches, reviews, and compiles a very comprehensive overview of the key MS highlights and abstracts from these meetings.
[Read more…]

Participants needed for new research studies and clinical trials

Participants needed for new research studies and clinical trials

The NeuroCommunity Foundation, in conjunction with the research community, want to ensure you have the opportunity to participate in research studies to help others and yourself. Your participation can assist researchers find new methods to prevent, detect or treat many neurological diseases.The following is a list of available research studies now recruiting interested participants. It is a small portion of the effort and dedication the research community places for advances in treatments for diseases that affect us all.  The following studies include aging, Parkinson’s disease, Multiple Sclerosis, Stroke and Traumatic Brain Injury.

[Read more…]

U.S.Senate Votes to Protect Medical Research Funding

U.S. Senate Votes to Protect Medical Research Funding

On Tuesday, June 7th,  the U.S. Senate protected important, innovative MS research funded by the Congressional Directed Medical Research Program (CDMRP) — thanks to MS activists!
MS activists’ outreach over the past week increased bipartisan co-sponsorship of the amendment and helped achieve this victory. More than 4,390 letters were sent and countless calls were made to Capitol Hill. As Senator McCain said during floor debate, “our phones have been ringing off the hook.”

If your Senator(s) voted for the amendment, please send him/her a thank you message.

The MS CDMRP received a $1 million increase in FY 2016–for a total of $6 million. In FY 2017, the House Appropriations Committee approved the same $6 million for the MS CDMRP. The Senate Appropriations Committee does not provide specific funding for the MS CDMRP, but has recommended a five percent increase over its 2016 funding level for medical research.

The NeuroCommunity Foundation:

For information about Parkinson’s disease and other movement disorders, support groups, wellness programs, education events, and local resources in northern Los Angeles county, Ventura county, Central Coast & Central Valley, contact us here or call 818-885-8623 to speak with Jan D. Somers MSW LCSW BCD, Education Director, Parkinson & Movement Disorder Information Center, The NeuroCommunity Foundation.

Zinbryta Injection Approved For Relapsing MS

FDA approved

On May 27th, the U.S. Food and Drug Administration (FDA) approved Zinbryta™ (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta™ is a long-acting injection that is self-administered by the patient monthly. [Read more…]

2016 MS Research Update Available Now

2016 MS Research Update

2016 MS Research Update

The 2016 MS Research Update published jointly by the Multiple Sclerosis Association of America (MSAA), the Consortium of Multiple Sclerosis Centers (CMSC), and the International Organization of MS Nurses (IOMSN), is available now for downloading and viewing, You can also order a print copy to be mailed to you. [Read more…]

Donation Information

I would like to make a donation in the amount of:

$200$100$50Other

I would like this donation to automatically repeat each month

Tribute Gift

Check here to donate in honor or memory of someone

Donor Information

First Name:
Last Name:
Email:
Add me to your mailing list
Phone:

Donor Address

Address:
Address 2:(optional)
City:
State :
Country:
Postal Code:

Shop with AmazonSmile and Support The NeuroCommunity Foundation

Did you know that you can support The NeuroCommunity Foundation through your everyday online purchases? Amazon.com has a charitable program called AmazonSmile. It is a simple and automatic way for you to support The NeuroCommunity Foundation every time you shop, at no cost to you.

When you shop at AmazonSmile, you’ll find the exact same low prices, vast selection and convenient shopping experience as Amazon.com, with the added bonus that the AmazonSmile Foundation will donate 0.5% of the purchase price to The NeuroCommunity Foundation!

It’s simple:

1) Go to AmazonSmile from the web browser on your computer or mobile device.
2)Login with your amazon.com username and password or create one if you are a new user.
3) Search for The NeuroCommunity Foundation in the search box on the right side where it asks which charity you would like to support.
4) Select The NeuroCommunity Foundation from the search results or type in The NeuroCommunity Foundation should the select not include our organization.
Happy shopping and thank you for supporting The NeuroCommunity Foundation

Support us when you shop for back-to-school items.

Just Click Here and Shop

Northridge Foundation For Neurological Research & Education

Smile with Back to School shopping

Dear The NeuroCommunity Foundation friends,supporters and participants.

If you happen to shop at Ralphs and would like to support The NeuroCommunity Foundation, we would be most appreciative!. If you do shop at Ralphs, we will receive 1 % of your purchase through their community
contribution program. The NeuroCommunity Foundation's Non-Profit Org. number ( NP0 # ) is 82287

All you need to do is enroll online at www.ralphs.com OR by calling Ralphs at
800-443-4438 after September 1, 2016.

If you happened to enroll prior to Sept 1st, Ralphs requires you to register again.

For your convenience, step-by-step website registration instructions are found below or can be found at www.ralphs.com, click on Community, click on Community Contributions, click on ‘Enroll Now’. If you don’t have computer access, please call us at 1-800-443-4438 for assistance.

Use you Ralph’s Rewards Card to Contribute Here’s How:

If you do not have a Ralph’s online account
1. Go to www.ralphs.com/account/create
2. Follow the easy steps to create an online account
3. You will be instructed to go to your email inbox to confirm your account
4. After you confirm your online account by clicking on the link in your email, return to
www.ralphs.com and click on ‘Sign In’, enter your email address and password.
5. View all your information and edit as necessary
6. Link your card to your organization by clicking on:
a. Community Rewards – Enroll
b. Type our NPO number 82287 or Neurocommunity.org
c. Remember to click on the circle to the left of your organizations’ name
d. Click on Enroll to finish your enrollment process

IF YOU HAVE ALREADY REGISTERED YOUR REWARDS CARD ON-LINE
(This means that you have already entered your email address and assigned yourself a password)

1. Log in to www.ralphs.com
2. Click Sign In
3. Enter your email address and password
4. Click on ‘Your Name’ (In the top right hand corner)
5. View all your information and edit as necessary
6. Link your card to your organization by clicking on:
a. Community Rewards – Re-Enroll
b. Type your NPO number or Name of your Organization
c. Remember to click on the circle to the left of your organizations’ name
d. Click on Enroll to finish your enrollment process